Key facts
- This page summarizes Peter H. Griffith's Form 4 filing for AMGEN INC (AMGN).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 20 Mar 2024, 20:05.
Peter H. Griffith - 18 Mar 2024 Form 4 Insider Report for AMGEN INC (AMGN)
- Reporting relationship
- EVP & CFO
- Issuer ticker
- AMGN
- Reported as of
- 18 Mar 2024
- Net transaction value
- -$1,389,520
- SEC form
- 4
- Accepted by SEC
- 20 Mar 2024, 20:05:33 UTC
- Prior SEC filing
- 08 Mar 2024
- Next SEC filing
- 01 May 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Peter H. Griffith
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Peter H. Griffith filed Form 4 for AMGEN INC (AMGN) on 20 Mar 2024.
Change
- Previous filing in this sequence was filed on 08 Mar 2024.
- Current net transaction value: -$1,389,520.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
AMGN
transaction
Common Stock
Tax liability
- Transaction value
- $1,389,520
- Shares
- -5,168
- Change %
- -13%
- Price
- $268.87
- Shares after
- 34,710
- Date
- 18 Mar 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 1,151 RSUs which will vest on 5/5/2024; 2,237 RSUs which will vest in installments of 1,102 on 4/30/2024 and 1,135 on 4/30/2025; 3,897 RSUs which will vest in two installments of 1,286 each on 5/2/2024 and 5/2/2025, and one installment of 1,325 on 5/2/2026; and 3,814 RSUs which will vest in installments of 1,258 on 5/2/2025, 1,259 on 5/2/2026 and 1,297 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
Footnote F2
These shares include 448 shares acquired, beginning on March 8, 2022 in amounts ranging between approximately 30 and 127 shares on the Company's quarterly dividend payout dates pursuant to a broker-administered DRIP meeting the requirements of Rule 16a-11.
Footnote F3
These shares include 779 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional amount.